Applicability of generic PBK modelling in chemical hazard assessment: A case study with IndusChemFate.

Applicability domain Generic PBK models In vitro IndusChemFate QIVIVE QSAR TNO Model Toxicokinetics

Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 02 03 2022
revised: 20 08 2022
accepted: 26 09 2022
pubmed: 12 11 2022
medline: 30 11 2022
entrez: 11 11 2022
Statut: ppublish

Résumé

Toxicology is moving away from animal testing towards in vitro tools to assess chemical safety. This new testing framework requires a quantitative method, i.e. kinetic modelling, which extrapolates effective concentrations in vitro to a bioequivalent human dose in vivo and which can be applied on "high throughput screening" of a wide variety of chemicals. Generic physiologically based kinetic (PBK) models help account for the role of toxicokinetics in setting human toxic exposure levels. Furthermore these models may be parameterized only on in silico QSARs and in vitro metabolism assays, thereby circumventing the use of in vivo toxicokinetics for this purpose. Though several such models exist their applicability domains have yet to be comprehensively assessed. This study extends previous evaluations of the PBK model IndusChemFate and compares it with its more complex biological complement ("TNO Model"). Both models were evaluated with a broad span of chemicals, varying regarding physicochemical properties. The results reveal that the "simpler" performed best, illustrating that IndusChemFate can be a useful first-tier for simulating toxicokinetics based on QSARs and in vitro parameters. Finally, proper quantitative in vitro to in vivo extrapolation conditions were illustrated starting with acetaminophen induced in vitro cytotoxicity in human HepaRG cells.

Identifiants

pubmed: 36367522
pii: S0273-2300(22)00154-4
doi: 10.1016/j.yrtph.2022.105267
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105267

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Styliani Fragki (S)

Center for Health Protection, RIVM, National Institute for Public Health and the Environment, P.O. Box 1, 3720, BA, Bilthoven, the Netherlands. Electronic address: stella.fragki@rivm.nl.

Aldert H Piersma (AH)

Center for Health Protection, RIVM, National Institute for Public Health and the Environment, P.O. Box 1, 3720, BA, Bilthoven, the Netherlands; Institute for Risk Assessment Sciences, Utrecht University, P.O. Box 80178, 3508, TD, Utrecht, the Netherlands.

Joost Westerhout (J)

TNO Innovation for Life, Princetonlaan 6 + 8, 3584, CB, Utrecht, the Netherlands.

Anne Kienhuis (A)

Center for Health Protection, RIVM, National Institute for Public Health and the Environment, P.O. Box 1, 3720, BA, Bilthoven, the Netherlands.

Nynke I Kramer (NI)

Institute for Risk Assessment Sciences, Utrecht University, P.O. Box 80178, 3508, TD, Utrecht, the Netherlands; Toxicology Division, Wageningen University, PO Box 8000, 6700, EA, Wageningen, the Netherlands.

Marco J Zeilmaker (MJ)

Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH